Voting Rights and Capital

Hikma Pharmaceuticals Plc
04 March 2008




Hikma Pharmaceuticals PLC - Voting Rights and Capital

LONDON, 4 March 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifies
the market that as at 29 February 2008 its capital consists of 188,053,607
ordinary shares with voting rights. There are no shares held in treasury.

The above figure (188,053,607) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC
under the FSA's Disclosure and Transparency Rules.

- ENDS -


Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles                           [phone]
Company Secretary


About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.
Hikma's operations are based principally in the Middle East and North Africa
('MENA') region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2006, the Group achieved revenues of $317 million
(2005 $262 million) and profit attributable to shareholders was $55 million
(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For
news and other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange